admin

Author Archives: admin

Cannabinoid Synergy With Hyperbaric Oxygen

Dr. Bogner’s presentation at AutismOne 2018 on Cannabinoid Synergy

The literature supports various pathophysiologies in individuals affected with autism spectrum disorder (ASD), including cerebral hypoperfusion, inflammation, mitochondrial dysfunction and oxidative stress. It has been hypothesized that children affected with ASD might benefit from Hyperbaric oxygen treatment (HBOT) owing to the increase in cerebral perfusion occurring during treatment. Here I present my theories on potential cannabinoid synergy with hyperbarics.

Watch the presentation below or YouTube | View or Download my Deck

The cell-danger response and endocannabinoid signaling pathways have been described as possible key elements in the pathophysiology of microglia driven neuroinflammation, with resulting behavioral problems associated with ASD.

Cannabinoid Synergy = Phytocannabinoid + Hyperbaric Oxygen Synergy

With the growing body of evidence in the literature that describes beneficial phytocannabinoid effects in patients affected with ASD, we highlight the principle mechanisms of a novel concept, e.g. phytocannabinoid-hyperbaric-oxygen synergy and its role in paving the way for faster and lasting clinical benefits. HBOT is approved for several clinical disorders including decompression sickness, gas gangrene, cyanide poisoning and diabetic wounds. Inhalation of above-atmospheric oxygen might result in an elevation of arterial partial pressure of oxygen, leading to increased oxygen delivery to the brain.

Cannabinoid Synergy with HBOTHBOT might also have anti-inflammatory properties due to the reduction of pro-inflammatory cytokines (tumor necrosis factor–α, interferon-γ, and interleukins 1 and 6). Furthermore, HBOT might improve mitochondrial dysfunction, as well as up-regulate the production of antioxidant enzymes. While some studies suggest improved cerebral perfusion, others showed decreased markers of inflammation and did not worsen oxidative stress markers in children with ASD. In the reviewed studies, HBOT had minimal adverse effects and was well tolerated.

Most of the reviewed studies relied on changes in behavioral measurements, which may lag behind physiological changes. In our protocol, we utilize different ATAs in monoplace chambers for all ASD children. The molecular collusion of hyperbaric oxygen and phytocannabinoids suggests synergistic properties, aiding in anti-inflammation, detoxification, improved synaptic plasticity and central nervous system homeostasis.

The Highwire interview: Del Bigtree on Cannabis Science for Autism

In autism, major protective brain mechanisms become interrupted and neuroinflammation emerges. A variety of toxins are responsible for the consequential great demand for neuronal protection. This is where cannabis science comes in to play. And guess what? It’s backed by a lot of solid research. I can vouch for this: I’ve personally gathered cannabis papers for autism in the original Michigan petition 3 years ago and helped support 4 states’ petition as well. It’s a banker’s box full of the finest research papers.

Cannabis programs are implemented in 58% of all states in the United States, yet the federal government says it has no medicinal value and classifies it as dangerous as heroin (or natural peyote). What evidence is being defended to keep it that way? Congressional members are sticking their necks out to make sure individual states are not targeted by Jeff Sessions and the Feds.
 
Why is the FDA approving cannabis-like pharmaceuticals? When we dive into the more than 35,000 scientific articles that are available in regards to cannabis, we can clearly see that the current main stream narrative on its implementation in autism and other medical conditions is flawed. In a big way too.
 
 
Del wanted to get to the bottom of cannabis science for autism. He invited me to discuss the current status quo. Autism is just one of many conditions that respond to cannabis, with a safety profile that justifies de-scheduling on a federal level completely. The autism cannabis science we will present is just the tip of the iceberg. Cannabis is already heavily studied in other countries such as Israel. We will discuss some results of human trials and take a deeper look on the federal fraud of prohibition.

Where is the Cannabis Science for Autism?

John’s Hopkins University found a 25% reduction of overall annual mortality from opioids due to state cannabis program implementations. The science speaks volumes. It is time to de-schedule cannabis, not primarily to have states cash in billions of dollars, but to benefit the ones who really need need it: the patients who suffer and are dying of mostly ineffective and dangerous pharmaceutical intervention.

I want to thank Del Bigtree for creating the platform for the conversation and inviting me to help spread awareness on the cannabis science for autism spectrum disorders.

Cannabis Science for Autism with Dr. Christian Bogner

Cannabis Science for Autism with Dr. Christian Bogner on The HighWire Show with Del Bigtree